Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35403971/
Major discoveries have been made in genetics and epigenetics of HCL. Moreover, the importance of several signaling pathways and tumor microenvironment has been recently highlighted. These findings led to the...
Relevance: In this review, we will present an update on HCL and HCL-V, focusing on pathophysiology and recent therapeutic advances.
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia
Source : https://www.tandfonline.com/doi/abs/10.1080/14737140.2022.2064849?journalCode=iery20
Abstract The development of Bruton tyrosine kinase (BTK) inhibitors has significantly changed the treatment landscape for patients with Waldenström macroglobulinemia (WM). Ibrutinib was the first BTK inhibitor to receive FDA...
Expert opinion: BTK inhibitors are very effective in WM and have an overall response rate higher than 90%. The side effect profile of these medications is manageable, but does include a risk of atrial fibrillation, infection, and bleeding. The newer BTK inhibitors, such as acalabrutinib and zanubrutinib, are known to have less off-target...
Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35407474/
Several new drugs are progressively improving the life span of patients with B-cell chronic lymphocytic leukemia (CLL). However, the rapidly evolving standard of care precludes robust assessments of the incremental...
Conclusion/Relevance: Several new drugs are progressively improving the life span of patients with B-cell chronic lymphocytic leukemia (CLL). However, the rapidly evolving standard of care precludes robust assessments of the incremental clinical value of further innovative drugs. Therefore, we systematically reviewed comparative evidence on...
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
Source : https://www.nejm.org/doi/10.1056/NEJMoa2110297
Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton’s tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)–mediated...
Conclusions: Rilzabrutinib was active and associated with only low-level toxic effects at all dose levels. The dose of 400 mg twice daily was identified as the dose for further testing. Overall, rilzabrutinib showed a rapid and durable clinical activity that improved with length of treatment.
Real-world management of targeted therapies in chronic lymphocytic leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35350909/
The advent of novel targeted therapies, including B-cell receptor (BCR) pathway and B-cell lymphoma 2 (BCL2) inhibitors, has substantially changed the treatment paradigm for chronic lymphocytic leukemia (CLL). Although targeted...
Conclusion/Relevance: Ongoing studies continue to address questions regarding optimal sequencing of therapies, the role of treatment combinations, and the efficacy of next-generation novel agents. This review provides a comprehensive overview regarding the clinical management of targeted therapies for CLL and applies current literature to...